Abstract
Human visceral leishmaniasis (HVL) is the most severe clinical form of a spectrum of neglected tropical diseases caused by protozoan parasites of the genus Leishmania. Caused mainly by L. donovani and L. infantum/chagasi, HVL accounts for more than 50 000 deaths every year. Drug therapy is available but costly, and resistance against several drug classes has evolved. Here, we review our current understanding of the immunology of HVL and approaches to and the status of vaccine development against this disease.
Original language | English |
---|---|
Pages (from-to) | 1462-70 |
Number of pages | 9 |
Journal | Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases |
Volume | 17 |
Issue number | 10 |
DOIs | |
Publication status | Published - Oct 2011 |
Bibliographical note
© 2011 The Authors. Clinical Microbiology and Infection © 2011 European Society of Clinical Microbiology and Infectious Diseases.Keywords
- Animals
- Antigens, Protozoan
- Cytokines
- Dogs
- Drug Discovery
- Epitopes
- Humans
- Immunity, Cellular
- Leishmania
- Leishmaniasis Vaccines
- Leishmaniasis, Visceral
- Psychodidae
- Vaccination